Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only a small subset of claims are supported by the supplied label excerpts (notably class/mechanism and limited description detail). Most claims about generic status/patents and multiple indications/side effects are unsupported by the provided labeling content, and key safety label elements (boxed warning context and contraindications) are largely missing or not accurately represented from the provided excerpts.
Category Scores
Accurate Statements
Losartan potassium belongs to the class of drugs called angiotensin II receptor blockers (ARBs).
11 DESCRIPTION
Losartan potassium helps lower blood pressure by blocking the action of angiotensin II.
12.1 Mechanism of Action
Generic losartan potassium has the same route of administration as Cozaar.
11 DESCRIPTION
More serious side effects of losartan potassium can occur and may require medical attention.
6 ADVERSE REACTIONS (WARNING: FETAL TOXICITY) (partial)
Unsupported Statements
Losartan potassium is available as a generic medication.
No support in provided label excerpts (absent_from_the_label).
The patent protection for the original branded drug Cozaar (losartan potassium) has expired.
No support in provided label excerpts; patent/legal status not covered (absent_from_the_label).
The U.S. patent for Cozaar (losartan potassium) expired in 2010.
No support in provided label excerpts (absent_from_the_label).
The U.S. patent expiration allowed other manufacturers to enter the market with generic versions of losartan potassium.
No support in provided label excerpts (absent_from_the_label).
Numerous pharmaceutical companies manufacture generic losartan potassium.
No support in provided label excerpts (absent_from_the_label).
Generic losartan potassium is bioequivalent to the brand-name drug Cozaar.
No support in provided label excerpts (absent_from_the_label).
Generic losartan potassium contains the same active ingredient as Cozaar.
No support in provided label excerpts regarding generic equivalence/active ingredient comparison to Cozaar (absent_from_the_label).
Generic losartan potassium has the same dosage form as Cozaar.
No support in provided label excerpts (absent_from_the_label).
Generic losartan potassium has the same strength as Cozaar.
No support in provided label excerpts (absent_from_the_label).
Generic losartan potassium has the same performance characteristics as Cozaar.
No support in provided label excerpts (absent_from_the_label).
Regulatory agencies such as the U.S. FDA ensure that generic drugs meet the same standards for safety and effectiveness as their brand-name counterparts.
No support in provided label excerpts (absent_from_the_label).
Losartan potassium is prescribed to treat high blood pressure (hypertension).
No support in provided label excerpts under Indications and Usage (absent_from_the_label).
Losartan potassium is prescribed to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.
No support in provided label excerpts (absent_from_the_label).
Losartan potassium is prescribed to protect kidney function in patients with type 2 diabetes who have hypertension and proteinuria.
No support in provided label excerpts (absent_from_the_label).
Common side effects of losartan potassium can include dizziness.
While adverse reaction section is referenced generally, 'dizziness' is not supported by the supplied excerpt (absent_from_the_label).
Common side effects of losartan potassium can include fatigue.
Not supported by supplied adverse reaction excerpt (absent_from_the_label).
Common side effects of losartan potassium can include upper respiratory tract infection.
Not supported by supplied adverse reaction excerpt (absent_from_the_label).
Contradictions
Important Omissions
Boxed warning content should be explicitly reflected beyond a vague 'more serious side effects may occur' statement; pregnancy fetal toxicity language and its directive should be represented. Only a partial/indirect mention appears in the extracted claims.
Importance:
High
Indications: multiple specific labeled indications (hypertension and other approved uses) are not supported by the provided excerpts; material indication details are therefore omitted/uncorroborated by the supplied label sections.
Importance:
Moderate
Contraindications section content is not provided/covered in the excerpted claim set (e.g., pregnancy-related contraindication is not explicitly captured as such).
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several claims about safety (common side effects) and key pregnancy risk content are not supported by the provided label excerpts, and boxed warning/contraindication-related messaging is not adequately represented.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most extracted claims are absent from the provided FDA label excerpts, including generic/patent/regulatory equivalence statements and multiple indications and specific common adverse effects; boxed warning and pregnancy-related safety labeling are not adequately captured.
Suggested Improvement
Limit claims to those supported by the supplied label excerpts (e.g., ARB class and mechanism) and explicitly align boxed warning/pregnancy safety language and any contraindications/complete adverse reaction statements with the actual label text provided in the audit inputs.